Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Participants were recruited and enrolled at VACT West Haven, CT. Participants are aged 18 and older and have 3 months or more of continuous opioid therapy for chronic pain. Participants are actively prescribed 30-100mg of morphine equivalent opioid dose based on pharmacy records. Primary Care Providers will assent for patient participation.~Inclusion Criteria:~* Aged 18 and older~* 3 months of continuous opioid therapy for chronic pain;~* 30-100 mg morphine equivalent daily opioid dose based on pharmacy records of standing and as needed opioids prescribed.~* 28 (out of 70) on the 7-item Brief Pain Inventory (BPI) functional interference subscale at screening~* Numerical pain rating of 4 or greater (i.e., moderate pain or greater) at screening on the 11-point pain numerical rating scale (NRS)~* Females must (a) be using birth control pills or depo provera injections, or have an intrauterine device; or (b) be post-menopausal, or (c) have undergone surgically sterilization.~* Primary care provider's (PCP) assent for patient participation, ascertained via encrypted email or in-person query.~Exclusion Criteria:~* DSM-IV defined substance use disorder, except nicotine dependence. Participants known to using marijuana, including those who are apparently legally authorized to use marijuana by non-VHA providers, will be excluded since opioid dose escalation in regular marijuana users is contraindicated.~* Opioid therapy for palliative care~* Participation in another investigational pharmaceutical trial within 30 days of screening~* Pregnancy or lactation~* Recently decompensated medical illness necessitating inpatient hospitalization (past 30 days)~* Transaminases (aspartate aminotransferase/alanine aminotransferase) greater than five times the upper limit of normal within 90 days of assessment phase~* Not well-controlled psychiatric symptoms at the time of physician assessment, including suicidal ideation or untreated psychosis; or recently decompensated psychiatric illness necessitating inpatient hospitalization (past 30 days).~* Use of a moderate to strong CYP3A4 inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- buprenorphine/naloxone (Type: EXPERIMENTAL): induction onto buprenorphine/naloxone from opioid treatment
- opioid dose escalation (Type: ACTIVE_COMPARATOR): increase of up to 25% of current opioid dose

Based on this trial design, predict the completion outcome and termination type (if applicable).